Professor Hope Rugo shares her insights on the breast
cancer highlights of #ESMO23 meeting, and also how they apply them in clinical
practice. This was a really interesting meeting for breast cancer, we heard a
lot of updates about antibody drug conjugates , immunotherapy and endocrine
therapy.
- DESTINY-Breast04 trial: trastuzumab deruxtecan offers
added benefit for patients with HER2-low breast cancer
- BEGONIA Phase Ib/II trial: Datopotamab deruxtecan plus
Imfinzi demonstrated robust and durable tumour responses in 1st-line treatment
of patients with metastatic triple-negative breast cancer
- TROPION-Breast01 trial: a phase III trial that
investigated datopotamab deruxtecan.
- KEYNOTE-522: showed statistically significant and
clinically meaningful improvements in pCR and EFS with the addition of
pembrolizumab to chemotherapy in patients with early-stage TNBC.
- CHECKMATE-7FL: investigating neoadjuvant nivolumab plus
chemotherapy versus placebo plus chemotherapy followed by adjuvant nivolumab or
placebo plus endocrine therapy.
Video: https://medicaldigest.org/scientific-contents/interview:breast-cancer-highlights-esmo-2023-congress
